500mg Fulvestrant Versus Exemestane in MBC

Fudan University120 enrolled

Overview

500mg Fulvestrant versus Exemestane in MBC

500mg Fulvestrant versus Exemestane in Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors in clinical practice- a multicenter retrospective study

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal woman, age \> 18 years old * Diagnosed with ER/PR+，HER2- Metastatic Breast Cancer * Adjuvant treatment of Non-steroidal Aromatase Inhibitors * First line of Metastatic Breast Cancer is 500mg Fulvestrant or Exemestane for at least one month, starting from 2014.01.01-2017.06.01 * Available medical history Exclusion Criteria: * Incomplete medical history

Locations (1)

Biyun Wang, MD

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

PFS

Progression free survival

Time frame: 6 weeks

Secondary Outcomes

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.